文献速递中枢神经肿瘤放疗放疗物理与技术

利用机器学习和影像组学区分脑转移瘤立体定向放疗后的真性进展与放射性坏死

Distinguishing True Progression From Radionecrosis After Stereotactic Radiation Therapy for Brain Metastases With Machine Learning and Radiomics.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-05-24

本研究纳入约翰霍普金斯医疗系统中接受立体定向放射外科(SRS)治疗脑转移后因症状性增大而切除的患者,以及可能为治疗效应(病灶增大后自发消退)的病例,基于术前T1增强和T2 FLAIR MRI提取影像组学特征,构建IsoSVM模型。优化分类器在留一交叉验证中敏感度65.38%、特异度86.67%、AUC 0.81;神经放射科医生仅能分类73%的病例(敏感度97%、特异度19%)。作者认为影像组学有望区分治疗效应与真性进展,结果需在独立数据集中进一步验证。

要点

  • 基于影像组学特征的IsoSVM模型在留一交叉验证中敏感度65.38%、特异度86.67%、AUC 0.81。
  • 神经放射科医生仅能分类73%的病例,敏感度97%、特异度19%。
  • 作者认为影像组学有望区分SRS后治疗效应与真性进展,结果需在独立数据集中进一步验证。

核心结论

  • 影像组学有望区分SRS治疗的脑转移瘤中的治疗效应与真性进展。
  • 基于本机构队列影像组学特征构建的预测模型在交叉验证中表现良好。
  • 这些结果需在独立数据集中进一步验证。

研究设计与样本

  • 研究纳入约翰霍普金斯医疗系统中接受SRS治疗脑转移后因症状性增大而切除的患者,以及可能为治疗效应(病灶增大后自发消退)的病例。
  • 共识别66例患者的82个治疗病灶,其中77个病灶有病理确认。
  • 在术前T1增强和T2 FLAIR MRI上半自动分割病灶,使用内部开发软件提取影像组学特征,每个序列每个病灶提取51个特征。
  • 采用单变量逻辑回归筛选表现最佳的特征,进入IsoSVM混合特征选择/分类模型,通过留一交叉验证进行参数优化和进一步特征选择,最终模型性能通过10折交叉验证重复100次评估。
  • 所有病例由一名委员会认证的神经放射科医生独立审查以作比较。

主要发现

  • 基于排名靠前影像组学特征的优化IsoSVM分类器在留一交叉验证中敏感度65.38%、特异度86.67%、AUC 0.81。
  • 神经放射科医生仅能分类73%的病例,敏感度97%、特异度19%。

局限性

  • 这些结果需在独立数据集中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Treatment effect or radiation necrosis after stereotactic radiosurgery (SRS) for brain metastases is a common phenomenon often indistinguishable from true progression. Radiomics is an emerging field that promises to improve on conventional imaging. In this study, we sought to apply a radiomics-based prediction model to the problem of diagnosing treatment effect after SRS. METHODS AND MATERIALS: We included patients in the Johns Hopkins Health System who were treated with SRS for brain metastases who subsequently underwent resection for symptomatic growth. We also included cases of likely treatment effect in which lesions grew but subsequently regressed spontaneously. Lesions were segmented semiautomatically on preoperative T1 postcontrast and T2 fluid-attenuated inversion recovery magnetic resonance imaging, and radiomic features were extracted with software developed in-house. Top-performing features on univariate logistic regression were entered into a hybrid feature selection/classification model, IsoSVM, with parameter optimization and further feature selection performed using leave-one-out cross-validation. Final model performance was assessed by 10-fold cross-validation with 100 repeats. All cases were independently reviewed by a board-certified neuroradiologist for comparison. RESULTS: We identified 82 treated lesions across 66 patients, with 77 lesions having pathologic confirmation. There were 51 radiomic features extracted per segmented lesion on each magnetic resonance imaging sequence. An optimized IsoSVM classifier based on top-ranked radiomic features had sensitivity and specificity of 65.38% and 86.67%, respectively, with an area under the curve of 0.81 on leave-one-out cross-validation. Only 73% of cases were classifiable by the neuroradiologist, with a sensitivity of 97% and specificity of 19%. CONCLUSIONS: Radiomics holds promise for differentiating between treatment effect and true progression in brain metastases treated with SRS. A predictive model built on radiomic features from an institutional cohort performed well on cross-validation testing. These results warrant further validation in independent datasets. Such work could prove invaluable for guiding management of individual patients and assessing outcomes of novel interventions.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Peng L, Parekh V, Huang P, et al. Distinguishing True Progression From Radionecrosis After Stereotactic Radiation Therapy for Brain Metastases With Machine Learning and Radiomics. Int J Radiat Oncol Biol Phys. 2018. PMID: 30353872. doi:10.1016/j.ijrobp.2018.05.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。